JHEP Reports

Papers
(The H4-Index of JHEP Reports is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Increased carbohydrate deficient transferrin: Whisky or candy?181
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”163
Copyright and information125
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]124
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”117
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer93
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication74
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation73
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association73
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives63
Copyright and information60
A small animal model of chronic hepatitis E infection using immunocompromised rats59
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st59
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort57
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates56
Emerging roles of circular RNAs in liver cancer54
MELD 3.i: A Bayesian Updating to the Model for End-Stage Liver Disease53
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?50
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD49
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis48
Epigenetics of alcohol-related liver diseases47
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis46
Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”43
Predicting liver ablation volumes with real-time MRI thermometry42
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice42
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis41
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes41
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging41
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis40
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool40
Time for a globally unified chronic HBV terminology?40
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data40
Editorial Board page36
Copyright and information35
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH35
0.058747053146362